Faeth Therapeutics reports second-quarter 2026 results, awaits endometrial cancer data

Faeth Therapeutics, trading on Nasdaq under the ticker "FTH," reported financial results for the quarter ended June 30, 2026 on August 4, 2026. Chief Executive Officer Anand Parikh said the company looks forward to reading out topline data from its Phase 2 PIK-201 trial in endometrial cancer, expected by year-end.¹

The company's pipeline also advanced in its second indication. Parikh noted the company dosed the first patient in its PIK-101 trial in HR+ breast cancer in April, with initial safety and efficacy data expected in 2027.¹ PIKTOR is being evaluated in the Phase 2 FTH-PIK-201 trial in second-line advanced endometrial cancer, with topline data anticipated in the second half of 2026, and in the Phase 1b/2 FTH-PIK-101 trial in HR+/HER2-advanced breast cancer, where the first patient was dosed in April 2026 and interim data is anticipated in 2027.¹

Corporate changes accompanied the quarter. Parikh said the combination with Sensei Biotherapeutics was an important milestone, and that a concurrent $200 million PIPE financing gave the company capital to pursue its multi-nodal hypothesis in multiple cancers.¹ In June, stockholders approved conversion of Series B preferred stock from the February 2026 acquisition and concurrent private placement into common stock, and the company changed its name to Faeth Therapeutics, Inc., trading under "FTH."¹ Anand Parikh was appointed Chairman, President and CEO, Brian Stephenson was appointed CFO, and the board added former FDA Commissioner Stephen M. Hahn and Saira Ramasastry.¹

On cash position, cash, cash equivalents and marketable securities totaled $186.4 million as of June 30, 2026, compared with $21.2 million as of December 31, 2025.¹